MK-8141

MK-8141 (also known as ACT-077825) is a small molecule renin inhibitor developed by Merck & Co. for the treatment of hypertension. It acts by inhibiting renin, an enzyme involved in the renin–angiotensin–aldosterone system (RAAS), which plays a key role in blood pressure regulation. In clinical studies, MK-8141 demonstrated substantial increases in immunoreactive active renin but did not result in significant or sustained reductions in plasma renin activity or blood pressure compared to placebo and active comparators such as enalapril. The drug was generally well tolerated but did not show significant antihypertensive efficacy[4][5][8].

Other names

3,9-diazabicyclo(3.3.1)non-6-ene-6-carboxamide N-cyclopropyl-7-(4-(2-(2,6-dichloro-4-methoxyphenoxy)ethoxy)phenyl)-5-methyl-, (3R,6S)-CAS# 903579-36-2